Menactra Sanofi Pasteur - Treatment for Protection Against Meningococcal Disease

Menactra is the first quadrivalent conjugate vaccine licensed in the U.S. for the prevention of meningococcal disease and is designed to offer protection against four serogroups of Neisseria meningitidis (A, C, Y, W-135), the bacterium that causes meningococcal infection.

Posted: January 2005

Related Articles:

Menactra (meningococcal conjugate vaccine) FDA Approval History

View comments

Hide
(web2)